Recombinant EBOV GPDTM (mammalian)

(No reviews yet) Write a Review
SKU:
0501-001
Availability:
Next week
€545
Frequently bought together:

Description

Recombinant EBOV GPDTM (mammalian) is available at Gentaur for Next Week Delivery.

Product Type: protein

Host: N/A

Clonality: N/A

Applications: ELISA, WB

Description: Mature, recombinant, HA-tagged ebolavirus glycoprotein minus the transmembrane domain (EBOV rGPΔTM) is supplied as purified protein. EBOV rGPΔTM is produced in mammalian cells and is purified by FPLC.

Storage: 2-3 weeks at -20◦C, -80◦C long term

Size: 100 µg of protein is supplied in PBS at a concentration of 0.876 mg/mL. The theoretical
molecular weight of the protein is ~70.5 kDa including the HA-tag, without glycosylation. Because of the highly
glycosylated nature of this protein, migration in an SDSPAGE gel is slowed resulting in broad, diffuse bands representing differing glycosylation forms.

Relevance: Recombinant glycoprotein provides a means for antibody development, control protein for testing,
and a tool to enhance research.

Western Blot: Quality control testing demonstrates strong detection of GP null under reduced conditions
down to 50 ng when using IBT’s monoclonal antibody 4F3 (cat# 0201-020) at 0.5 g/mL.

SDS-PAGE & Western Blot Detection


(A) SDS-PAGE and stain demonstrating 5 g, 1 g (lane 1,
2 respectively) of EBOV rGPΔTM HA-Tag protein under
denaturing and reducing conditions. MW denotes Novex
Sharp prestained protein markers. (B) Western blot
detection of EBOV rGPΔTM at 500 ng, 100 ng, and 50 ng
(lanes 1-3). EBOV rGPΔTM was detected using IBT’s
monoclonal antibody 4F3 (cat# 0201-020) at 0.5 g/mL
and anti-mouse IgG-HRP conjugate, followed by TMB
substrate.
ELISA Data

Plate was coated with EBOV rGPΔTM starting at 800
ng/well, serially diluted in DPBS. Washed plate was
detected using one dilution of a positive control serum,
followed with anti-IgG HRP conjugate and TMB
substrate. OD650 is reported.

View AllClose

Additional Information

Size:
100ug
View AllClose

0 Reviews

View AllClose